genedrive plc
("genedrive" or the
"Company")
Result of AGM
genedrive plc (AIM: GDR), the point
of care pharmacogenetic testing company, announces that at the Annual General Meeting, held today, all
resolutions proposed were duly passed.
For information, details of the
proxy voting are shown below:
|
Resolution
|
Votes
For
|
Votes
For
(as % of
votes cast)
|
Votes
Against
|
Votes
Against
(as % of
votes cast)
|
Vote
Withheld
|
|
1
|
60,337,408
|
96.9%
|
1,932,301
|
3.1%
|
44,070
|
|
2
|
54,051,527
|
89.5%
|
6,370,692
|
10.5%
|
1,891,560
|
|
3
|
56,234,467
|
90.4%
|
5,972,194
|
9.6%
|
107,118
|
|
4
|
56,232,855
|
90.4%
|
5,973,806
|
9.6%
|
107,118
|
|
5
|
54,614,002
|
89.9%
|
6,155,707
|
10.1%
|
1,544,070
|
|
6
|
56,585,659
|
90.9%
|
5,684,050
|
9.1%
|
44,070
|
|
7
|
41,714,611
|
67.0%
|
20,555,098
|
33.0%
|
44,070
|
|
8
|
58,270,899
|
93.6%
|
3,980,810
|
6.4%
|
62,070
|
|
9
|
52,909,558
|
87.3%
|
7,705,575
|
12.7%
|
1,698,646
|
|
10
|
49,491,977
|
81.7%
|
11,079,156
|
18.3%
|
1,742,646
|
|
11
|
52,535,894
|
86.7%
|
8,035,239
|
13.3%
|
1,742,646
|
The full text of each of the
resolutions is set out in the notice of Annual General Meeting,
copies of which are available on the Company's website
(www.genedriveplc.com).
Although all the resolutions were
passed, the Board of genedrive notes that more than 20% of votes
were cast against the reappointment of one of the directors.
While the Board believes that this director brings considerable
experience and expertise to the Board, it intends to engage with
shareholders to better understand their concerns on the resolution
in question.
For further details please contact:
|
genedrive plc
|
+44 (0)161
989 0245
|
|
Gino Miele: CEO / Russ Shaw:
CFO
|
|
|
|
|
|
Peel
Hunt LLP (Nominated Adviser and Broker)
|
+44 (0)20
7418 8900
|
|
James Steel / Patrick
Birkholm
|
|
|
|
|
|
Walbrook PR Ltd (Media & Investor
Relations)
|
+44 (0)20
7933 8780 or genedrive@walbrookpr.com
|
|
Anna Dunphy
|
+44
(0)7876 741 001
|
About
genedrive plc (http://www.genedriveplc.com)
genedrive plc is a pharmacogenetic testing
company developing and commercialising a low cost, rapid, versatile
and simple to use point of need pharmacogenetic platform for the
diagnosis of genetic variants. This helps clinicians to quickly
access key genetic information that will aid them make the right
choices over the right medicine or dosage to use for an effective
treatment, particularly important in time-critical emergency care
healthcare paradigms. Based in the UK, the Company is at the
forefront of Point of Care pharmacogenetic testing in emergency
healthcare. Pharmacogenetics informs on how your individual
genetics impact a medicines ability to work for you. Therefore, by
using pharmacogenetics, medicine choices can be personalised, made
safer and more effective. The Company has launched its two flagship
products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19
ID Kit, both developed and validated in collaboration with NHS
partners and deployed on its point of care thermocycler platform.
Both tests are single-use disposable cartridges which are ambient
temperature stable, circumventing the requirement for cold chain
logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a
worlds-first and allows clinicians to make a decision on antibiotic
use in neonatal intensive care units within 26 minutes, ensuring
vital care is delivered, avoiding adverse effects potentially
otherwise encountered and with no negative impact on the patient
care pathway. Its CYP2C19 ID Kit which has no comparably positioned
competitor currently allows clinicians to make a decision on the
use of Clopidogrel in stroke patients in 70 minutes, ensuring that
patients who are unlikely to benefit from or suffer adverse effects
from Clopidogrel receive an alternative antiplatelet therapeutic in
a timely manner, ultimately improving outcomes. Both tests have
undergone review by the National Institute for Health and Care
Clinical Excellence ("NICE") and have been recommended for use in
the UK NHS.
The Company has a clear commercial strategy
focused on accelerating growth through maximising in-market sales,
geographic and portfolio expansion and strategic M&A, and
operates out of its facilities in Manchester.